SEBI Reg. Investment Advisor

Download App

MoneyWorks4Me

The sales is pegged at Rs. 49238.80 millions for the March 2026 quarter. The mentioned figure indicates a decline of about -31.42% as against Rs. 71794.50 millions during the year-ago period.The Net Profit of the company slipped to Rs. 6087.00 millions from Rs. 20419.70 millions, a decline of -70.19% on QoQ basis.Operating Profit reported a sharp decline to 13919.00 millions from 31915.80 millions in the corresponding previous quarter.


(Rs. in Million)


  Quarter ended Year to Date Year ended
  202603 202503 % Var 202603 202503 % Var 202603 202503 % Var
Sales 49238.80 71794.50 -31.42 207546.40 229774.00 -9.67 207546.40 229774.00 -9.67
Other Income 629.30 1321.30 -52.37 4193.30 3791.40 10.60 4193.30 3791.40 10.60
PBIDT 13919.00 31915.80 -56.39 66000.20 72168.40 -8.55 66000.20 72168.40 -8.55
Interest 2169.20 2323.80 -6.65 9478.40 9538.90 -0.63 9478.40 9538.90 -0.63
PBDT 11749.80 29592.00 -60.29 51058.40 62629.50 -18.48 51058.40 62629.50 -18.48
Depreciation 3259.70 3054.40 6.72 13117.20 12867.40 1.94 13117.20 12867.40 1.94
PBT 8490.10 26537.60 -68.01 37941.20 49762.10 -23.75 37941.20 49762.10 -23.75
TAX 2403.10 6117.90 -60.72 11707.00 7481.30 56.48 11707.00 7481.30 56.48
Deferred Tax 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
PAT 6087.00 20419.70 -70.19 26234.20 42280.80 -37.95 26234.20 42280.80 -37.95
Equity 2399.30 2399.30 0.00 2399.30 2399.30 0.00 2399.30 2399.30 0.00
PBIDTM(%) 28.27 44.45 -36.41 31.80 31.41 1.25 31.80 31.41 1.25

Sun Pharma Inds. Share Price

1779.35 -10.10 (-0.56%)
04-Jun-2026 16:59 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1779.35
Dr. Reddys Lab 1267.05
Cipla 1397.75
Zydus Lifesciences 1085.45
Lupin 2248.70
View more..

About MoneyWorks4Me

MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.

Our Vision

To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.

What Makes MoneyWorks4Me Different

Our Approach: Ensuring compounding work its magic on client portfolio.

MoneyWorks4Me ensures this through:

×